CALC on Nasdaq
CalciMedica, Inc.
$1.09 up 0.02 (2.33%)Price as of Oct 15, 2026 at 17:33 UTC
Last updated Oct 16, 2026.
Overview
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Financial statements
Every line of the income statement in the latest annual report, as filed.9
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Research and development | $15.2M | $14.5M |
| General and administrative | $7.9M | $9.7M |
| Total operating expenses | $23.1M | $24.2M |
| Loss from operations | -$23.1M | -$24.2M |
| Change in fair value of financial instruments | -$6.0M | $9.5M |
| Interest expense | -$1.4M | $0 |
| Interest income | $713.0K | $1.0M |
| Other income | $268.0K | $0 |
| Total other income (expense) | -$6.4M | $10.5M |
| Net loss | -$29.6M | -$13.7M |
| Net loss per share - basic | -$1.97 | -$1.22 |
| Net loss per share - diluted | -$1.97 | -$1.22 |
| Weighted-average number of shares outstanding used in computing net loss per share - basic | 15.0M shares | 11.2M shares |
| Weighted-average number of shares outstanding used in computing net loss per share - diluted | 15.0M shares | 11.2M shares |
Every line of the balance sheet in the latest annual report, as filed.9
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Cash and cash equivalents | $11.5M | $7.9M | |
| Short-term investments | $1.5M | $10.7M | |
| Prepaid clinical trial expenses | $201.0K | $748.0K | |
| Other prepaid expenses and current assets | $259.0K | $248.0K | |
| Assets held for sale | $54.0K | $0 | |
| Total current assets | $13.5M | $19.7M | |
| Property and equipment, net | $50.0K | $119.0K | |
| Other assets | $11.0K | $10.0K | |
| Total assets | $13.6M | $19.8M | |
| Accounts payable | $1.2M | $2.0M | |
| Accrued clinical trial costs | $1.1M | $820.0K | |
| Accrued expenses | $290.0K | $866.0K | |
| Current portion, promissory note | $1.2M | $0 | |
| Total current liabilities | $3.8M | $3.7M | |
| Promissory note | $8.4M | $0 | |
| Warrant liability | $8.0M | $1.7M | |
| Total liabilities | $20.2M | $5.4M | |
| Preferred stock, $0.0001 par value; 10,000,000 shares authorized at December 31, 2025 and December 31, 2024, respectively; no shares issued and outstanding at December 31, 2025 and December 31, 2024, respectively | $0 | $0 | |
| Common stock, $0.0001 par value; 500,000,000 shares authorized at December 31, 2025 and December 31, 2024, respectively; 15,437,410 and 13,481,917, issued and outstanding at December 31, 2025 and December 31, 2024, respectively | $4.0K | $4.0K | |
| Additional paid-in capital | $182.7M | $174.2M | |
| Accumulated deficit | -$189.3M | -$159.8M | |
| Accumulated other comprehensive income | $0 | $4.0K | |
| Total stockholders' equity (deficit) | -$6.6M | $14.4M | $8.2M |
| Total liabilities and stockholders' equity (deficit) | $13.6M | $19.8M | |
| Preferred stock, par value | $0.00 | $0.00 | |
| Preferred Stock, Shares Authorized | 10.0M shares | 10.0M shares | |
| Preferred Stock, Shares Issued | 0 shares | 0 shares | |
| Preferred Stock, Shares Outstanding | 0 shares | 0 shares | |
| Common stock par value | $0.00 | $0.00 | |
| Common stock, shares authorized | 500.0M shares | 500.0M shares | |
| Common stock, shares issued | 15.4M shares | 13.5M shares | |
| Common stock, shares outstanding | 15.4M shares | 13.5M shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow in the latest annual report, as filed.9
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Net loss | -$29.6M | -$13.7M |
| Stock-based compensation expense | $3.0M | $2.3M |
| Depreciation | $46.0K | $58.0K |
| Change in the fair value of warrant liability | $5.2M | -$9.5M |
| Change in the fair value of promissory note | $777.0K | $0 |
| Promissory note issuance costs | $336.0K | $0 |
| Transaction costs associated with warrants | $0 | $776.0K |
| Accretion of discount on short-term investments | -$345.0K | -$608.0K |
| Change in unrealized losses on investments | -$1.0K | $0 |
| Prepaid expenses, other current and non-current assets | $536.0K | -$228.0K |
| Accounts payable | -$840.0K | $601.0K |
| Accrued expenses and other liabilities | -$319.0K | -$868.0K |
| Net cash used in operating activities | -$21.2M | -$21.1M |
| Purchase of investments | -$15.9M | -$29.0M |
| Maturity of investments | $25.5M | $24.6M |
| Purchases of property and equipment | -$28.0K | -$8.0K |
| Net cash provided by (used in) investing activities | $9.6M | -$4.4M |
| Proceeds from issuance of common stock, net of issuance costs | $8.0K | $27.9M |
| Proceeds from exercise of stock options | $25.0K | $20.0K |
| Proceeds from issuance of promissory note, net | $9.7M | $0 |
| Proceeds from issuance of common stock from ATM Facility, net of issuance costs | $5.5M | $49.0K |
| Net cash provided by financing activities | $15.2M | $28.0M |
| Net increase in cash and cash equivalents | $3.6M | $2.4M |
| Cash paid for interest | $1.1M | $0 |
| Financing costs included in accounts payable and accrued expenses | $3.0K | $78.0K |
| Equipment purchases included in accounts payable | $3.0K | $0 |
Former names
Recent filings
- Oct 5, 20264
- Oct 5, 20264
- Oct 5, 20264
- Oct 5, 20264
- Oct 5, 20264
- Sep 30, 2026424B5
- Sep 30, 20268-K
- Sep 28, 20264
- Sep 28, 20264
- Sep 28, 20264
- Sep 28, 20264
- Sep 23, 2026S-8
- Sep 16, 20268-K
- Sep 2, 20268-K
- Aug 27, 20268-K
Every filing from the last three years, summarized. The full record is on SEC EDGAR.1
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2Yahoo FinanceCALC quote
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12